This study compares treatment outcomes between patients of African American/Black (AA)
ancestry and European American/White (EA) ancestry currently receiving immune checkpoint
inhibitor treatment. Collecting samples of blood and saliva and health and treatment
information from racially diverse patients receiving immune checkpoint inhibitor treatment
over time may help doctors better understand health care disparities among all cancer
patients.
Intervention
Condition
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Investigators
Charles S Kamen, PhD, Song Yao, PhD, Jay W. Carlson, Bryan A. Faller